Luseogliflozin Suppresses Fine Glycemic Fluctuation Late at Night: New Aspect of SGLT2 Inhibitor

被引：0
|
作者：
Yamauchi, Keishi
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-798-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
798-P
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
    Nakatsu, Yusuke
    Kokubo, Hiroki
    Bumdelger, Batmunkh
    Yoshizumi, Masao
    Yamamotoya, Takeshi
    Matsunaga, Yasuka
    Ueda, Koji
    Inoue, Yuki
    Inoue, Masa-Ki
    Fujishiro, Midori
    Kushiyama, Akifumi
    Ono, Hiraku
    Sakoda, Hideyuki
    Asano, Tomoichiro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [32] Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice
    Hata, Shinnosuke
    Okamura, Takuro
    Kobayashi, Ayaka
    Bamba, Ryo
    Miyoshi, Tomoki
    Nakajima, Hanako
    Kitagawa, Nobuko
    Hashimoto, Yoshitaka
    Majima, Saori
    Senmaru, Takafumi
    Okada, Hiroshi
    Ushigome, Emi
    Nakanishi, Naoko
    Takakuwa, Hiroshi
    Sasano, Ryoichi
    Hamaguchi, Masahide
    Fukui, Michiaki
    NUTRIENTS, 2022, 14 (17)
  • [33] The Effect of Luseogliflozin (TS-071), a Selective SGLT2 Inhibitor, on Pharmacodynamics and Pharmacokinetics in Japanese Type 2 Diabetic Subjects With Renal Impairment
    Haneda, Masakazu
    Seino, Yutaka
    Sasaki, Takashi
    Fukatsu, Atsushi
    Samukawa, Yoshishige
    Sakai, Soichi
    Sato, Yuri
    Watanabe, Takashi
    DIABETES, 2012, 61 : A273 - A273
  • [34] Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycaemic control in Japanese type 2 diabetic subjects with renal impairment
    Haneda, M.
    Seino, Y.
    Fukatsu, A.
    Sasaki, T.
    Samukawa, Y.
    Sakai, S.
    Sato, Y.
    Watanabe, T.
    DIABETOLOGIA, 2012, 55 : S303 - S303
  • [35] Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients
    Inagaki, N.
    Seino, Y.
    Sasaki, T.
    Fukatsu, A.
    Ubukata, M.
    Umeuchi, H.
    Sakai, S.
    Samukawa, Y.
    DIABETOLOGIA, 2013, 56 : S82 - S82
  • [36] Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
    Aroor, Annayya R.
    Das, Nitin A.
    Carpenter, Andrea J.
    Habibi, Javad
    Jia, Guanghong
    Ramirez-Perez, Francisco I.
    Martinez-Lemus, Luis
    Manrique-Acevedo, Camila M.
    Hayden, Melvin R.
    Duta, Cornel
    Nistala, Ravi
    Mayoux, Eric
    Padilla, Jaume
    Chandrasekar, Bysani
    DeMarco, Vincent G.
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [37] Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
    Annayya R. Aroor
    Nitin A. Das
    Andrea J. Carpenter
    Javad Habibi
    Guanghong Jia
    Francisco I. Ramirez-Perez
    Luis Martinez-Lemus
    Camila M. Manrique-Acevedo
    Melvin R. Hayden
    Cornel Duta
    Ravi Nistala
    Eric Mayoux
    Jaume Padilla
    Bysani Chandrasekar
    Vincent G. DeMarco
    Cardiovascular Diabetology, 17
  • [38] Tofogliflozin, a Novel, Potent, and Highly Selective SGLT2 Inhibitor, Improves Glycemic Control in Diabetic Mice and Rats
    Suzuki, Masayuki
    Honda, Kiyofumi
    Fukazawa, Masanori
    Ozawa, Kazuharu
    Hagita, Hitoshi
    Kawai, Takahiro
    Ikeda, Sachiya
    DIABETES, 2011, 60 : A312 - A312
  • [39] Luseogliflozin (TS-071) a Novel, Potent and Selective SGLT2 Inhibitor, Did not Affect the PK of Several Oral Diabetic Agents in Clinical
    Nakai, Yasuhiro
    Mutoh, Masaru
    DIABETES, 2012, 61 : A607 - A607
  • [40] Protective Effects of SGLT2 Inhibitor Luseogliflozin on Pancreatic Beta Cells in Obese Diabetic db/db Mice-"The Earlier and Longer, the Better"
    Kimura, Tomohiko
    Shimoda, Masashi
    Nakanishi, Shuhei
    Mune, Tomoatsu
    Kaku, Kohei
    Kaneto, Hideaki
    DIABETES, 2018, 67
12345